Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial (HAICAT)

NCT02767375 Phase 2/Phase 3 UNKNOWN

To study if the addition of HAIC following complete removal of early stage liver cancer of HCC will prevent or delay the recurrence of the disease. Half of the participant will receive two cycles of the HAIC after the hepatectomy, while the other half will return to the baseline surveillance schedule.

Details

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	Phase 2/Phase 3
Status	UNKNOWN
Enrolment	192
Start date	2015-02
Completion	2018-12

Conditions

• Hepatocellular Carcinoma

Interventions

• Oxaliplatin(OXA), 5-fluorouracil (5-FU)
• Hepatic arterial catheter implantation

Primary outcomes

• Recurrence Free Survival — approximately 70 months from first patient first visit

Countries

China